Overview

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) of not taking the medication for a maximum of 6 days over a 28-day study treatment period.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride
Methylphenidate